Strattera (Atomoxetine Hydrochloride)
Brand Names: Strattera
Methodology & AI Transparency ⓘ
Strattera (Atomoxetine Hydrochloride) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the Norepinephrine Reuptake Inhibitor category, Strattera provides branded delivery of active moiety Atomoxetine Hydrochloride (cross-referenced at /meds/atomoxetine-hydrochloride) (registered by Eli Lilly and Company; NDC 0002-3227, 0002-3238).
- 2 Real-world patient consensus: Registered under RxNorm 349592 and SPL 2026-06-30, pairing Strattera packaging with active ingredient Atomoxetine Hydrochloride.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $9.06 wholesale mail-order against $34.50 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Strattera (Atomoxetine Hydrochloride) tolerability events: nausea (12.4%), dizziness (6.7%), fatigue (6.5%).
Ask our AI Specialists anything about Strattera (Atomoxetine Hydrochloride)
Strattera (Atomoxetine Hydrochloride) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the Norepinephrine Reuptake Inhibitor category, Strattera provides branded delivery of active moiety Atomoxetine Hydrochloride (cross-referenced at /meds/atomoxetine-hydrochloride) (registered by Eli Lilly and Company; NDC 0002-3227, 0002-3238). Characterized by 18 mg/1 Capsule; 10 mg/1 Capsule under 2026-06-30 SPL documentation, Strattera targets 1 Indications and usage strattera: is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in.
Through its Atomoxetine Hydrochloride active moiety, Strattera exerts norepinephrine reuptake inhibitor activity involving CYP2D6 clearance pathways. Registered under NDC 0002-3227, 0002-3238 (registered by Eli Lilly and Company; effective 2026-06-30), the 18 mg/1 Capsule; 10 mg/1 Capsule presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (349592) and CMS NADAC ($12.6575/unit) ledgers.
Systemic exposure to Strattera (Atomoxetine Hydrochloride) reflects F ≈ 70%–82% systemic availability after standard oral Strattera (Atomoxetine Hydrochloride) administration absorption kinetics and strattera (atomoxetine hydrochloride) undergoes cyp2d6-mediated hepatic metabolism prior to excretion, sustaining receptor engagement across a Terminal t½ estimated at 10–15 hrs depending on renal/hepatic reserve (Strattera (Atomoxetine Hydrochloride)) half-life window (time to peak concentration spans 1 to 4 hrs under strattera (atomoxetine hydrochloride) maintenance response profile).
Dosing protocols (18 mg/1 Capsule or 10 mg/1 Capsule or 80 mg/1 Capsule or 25 mg/1 Capsule or 60 mg/1 Capsule) balance efficacy (78.00% patient satisfaction across 22 logs) against nausea (12.4% of reports), somnolence (7.4% of reports), constipation (6.9% of reports), with strict avoidance in severe drug-induced hypersensitivity to atomoxetine hydrochloride or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-06-30 for strattera (atomoxetine hydrochloride).
Allow at least two weeks between MAOI discontinuation and Strattera (Atomoxetine Hydrochloride) dosing to prevent neurotransmitter toxicity.
Review concurrent CYP2D6 substrates and inhibitors when titrating Strattera (Atomoxetine Hydrochloride) maintenance doses.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Atomoxetine Hydrochloride or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-06-30 for Strattera (Atomoxetine Hydrochloride)
Logged Side-Effect Incidence (22 Reports)
Strattera (Atomoxetine Hydrochloride) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Strattera (Atomoxetine Hydrochloride))
Human clinical trial evidence for Strattera (Atomoxetine Hydrochloride) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Strattera (Atomoxetine Hydrochloride) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $12.6575/unit (~$379.73/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $9.06 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $10.42 / mo | View logs ↓ |
Strattera (Atomoxetine Hydrochloride) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Strattera (Atomoxetine Hydrochloride) RxNorm Concept ID | 349592 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $12.6575 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $9.06 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 78.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Strattera (Atomoxetine Hydrochloride) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Strattera (Atomoxetine Hydrochloride) (norepinephrine reuptake inhibitor) monograph synthesizing RxNorm 349592, openFDA FAERS signals, and $9.06–$34.50 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Strattera (Atomoxetine Hydrochloride) community threads and patient logs by age, biological sex, dosage, and treatment duration.